Cure8 trial brief
Cardiovascular disease is an important extraintestinal concern for people with IBD, and current risk scores may miss IBD-specific drivers. This study aims to track heart and vascular events in IBD and find biomarkers that better predict risk.
Patients with Crohn’s disease or ulcerative colitis; clinicians managing IBD and cardiovascular risk; researchers in IBD complications, biomarkers, multi-omics, or AI-based prediction.
This is a registered, prospective observational study (PROVACI) recruiting patients with Crohn’s disease or ulcerative colitis and age-/gender-matched controls to track major cardiovascular events (MACEs) over a two-year follow-up and to search for predictive biomarkers using multi‑omics and artificial intelligence.
The study plans to enroll about 600 participants, collect baseline cardiovascular risk scores and comprehensive clinical data, and record specific events such as myocardial infarction, stroke, transient ischemic attack, heart failure, atrial fibrillation, acute arterial embolism, and ischemic angina.
Multi-omics analyses and AI methods are intended to identify biomarkers linked to cardiovascular outcomes in IBD. Registry details (from ClinicalTrials.gov): observational, recruiting, single-country site at IRCCS San Donato Policlinic (Milan, Italy). Minimum age 16, planned 2‑year follow-up.
The protocol focuses on incidence of MACEs and predictive factor discovery rather than testing an interventional treatment.
How this may matter to someone with IBD People with Crohn’s disease or ulcerative colitis are being studied because cardiovascular disease is a notable extraintestinal risk in IBD; this study aims to improve risk prediction and find biological markers that could explain or forecast that risk.
ClinicalTrials.gov entry describes a recruiting, observational study with planned enrollment and follow-up; it is a protocol record and does not present study results. Findings will need peer review and validation.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This project aims to improve prediction of autoimmune disease onset and immunotherapy-related autoimmunity by combining genetics and plasma proteins.
A validated AI biomarker that predicts which IBD treatments are likely to work could reduce trial-and-error in treatment choices, potentially shortening time to effective therapy for people with Crohn's disease or...
This study suggests machine learning of stool microbiome data could eventually help distinguish IBD (especially Crohn’s) from healthy people and some other bowel or systemic conditions.
